Agios Pharmaceuticals (AGIO) Return on Capital Employed (2013 - 2026)

Agios Pharmaceuticals has reported Return on Capital Employed for 14 years, with the latest figure at 40.22% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1194.0% year-over-year to 40.22%; the trailing twelve-month figure through Mar 2026 stood at 40.22% (down 1194.0% YoY), and the FY2025 full-year result was 33.77%, up 115.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 40.22%, down from 37.49% in the prior quarter.
• The five-year high for Return on Capital Employed was 25.86% in Q4 2024, with the low at 54.1% in Q2 2024.
• Historically, Return on Capital Employed has averaged 36.1% across 5 years, with a median of 34.99% in 2024.
• Annual changes were most pronounced in 2024 — Return on Capital Employed sank 1886 bps — and 2025, when it jumped 2211 bps.
• Agios Pharmaceuticals' Return on Capital Employed stood at 33.92% in 2022, then declined by 28 bps to 43.29% in 2023, then jumped by 40 bps to 25.86% in 2024, then sank by 45 bps to 37.49% in 2025, then retreated by 7 bps to 40.22% in 2026.
• The last three Return on Capital Employed figures came in at 40.22% (Q1 2026), 37.49% (Q4 2025), and 35.13% (Q3 2025), per Business Quant data.